Turnspire Capital completed the acquisition of the nutraceuticals business unit of Ashland.

Turnspire Capital, a private equity firm, completed the acquisition of the nutraceuticals business unit of Ashland, a global specialty materials company serving customers in a wide range of consumer and industrial markets. Financial terms were not disclosed. “We are thrilled to acquire this great platform with strong formulation and manufacturing capabilities, underpinned by its portfolio of proprietary ingredients, that position it as a supplier of choice to global multinationals and emerging brands alike. As an independent company benefiting from Turnspire’s extensive experience transforming corporate carve-outs into thriving standalone companies, the Business can build upon its capabilities to achieve sustainable, profitable growth,” Ilya Koffman, Turnspire Managing Partner.